strategic drug repositioning exploit opportunities and accelerate r&d by re-profiling your drugs...

8
Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ [email protected] +1 917 653-0470

Upload: barbara-gregory

Post on 05-Jan-2016

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ bill@updatepharma.com +1

• Strategic Drug Repositioning

Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs

____________________________

[email protected]+1 917 653-0470

Page 2: Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ bill@updatepharma.com +1

William J. Garner, MD MPHManaging Director

Founded EGB Advisors in ’00 to “Drug Hunt”

Author, Garnering Capital (Amazon & Kindle)•Roche/Wall Street•Founder of 4 repositioning companies, 3 public

– Arbitrage over time and geography– ~$15M over three years to a new NDA

•Histopathology, Columbia-Presbyterian/Master of Public Health, Harvard

Page 3: Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ bill@updatepharma.com +1

Overview

• The Promise of Drug Repositioning • What makes a repositioned drug successful? • How are we to overcome the barriers to succeed? • Who has helped to make improvements in the field? • What does the future hold?

Page 4: Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ bill@updatepharma.com +1

Introduction

The costs associated with product development have increased dramatically while venture capital investment from ‘00 to ‘12 for early stage technologies has been limited.

Identifying key issues related to successful financing, commercialization, or partnering requires careful analysis and strategic planning.

Page 5: Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ bill@updatepharma.com +1

What makes a repositioned drug successful?

Technology Assessment–Unmet Medical Need Addressed–Reimbursement–Plan and execute Proof-of-Concept, and next-step studies, to increase value

Page 6: Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ bill@updatepharma.com +1

How are we to overcome the barriers to succeed?

–IP creation/analysis• Pre-clinical, pre-formulation studies

–Regulatory strategies

Page 7: Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ bill@updatepharma.com +1

Our Experiences Repositioning Drugs

• Oncology – DelMar Pharma (DMPI) & Update Pharma, Inc.– Each >40 clinical trials and an Ex-US

approval

• Urology – Urigen (URGP)– Procedure Code & Phase 2 Data Driven

• Pulmonology – Invion (ASX:IVX) formerly Inverseon

Page 8: Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ bill@updatepharma.com +1

Who has helped to make improvements in the field?

– GSK• Carvedilol• To this day, titration packs provide market exclusivity in

some markets• Billions in new sales

- Celgene

– Academics• Elmiron for Interstitial Cystitis, $200M per year